MRONJ: Pathophysiology
Salient information + drug info
MRONJ IS KNOWN AS MEDICATION RELATED OSTEONECROSIS OF THE JAW
MRONJ IS CAUSED BY BISPHOSPHONATES OR NON BISPHOSPHONATE MEDICATION
BISPHOSPHONATES ARE USED TO TREAT OSTEOPOROSIS, PAGET’S DISEASE AND SLOW CANCER SPREAD BY APOPTOSIS OF
OSTEOCLASTS (REDUCES RESORPTION OF BONE)
NON BISPHOSPHONATES ALSO TREAT THE SAME BONE CONDITions but have a different mechanism of action. They include
monoclonal antibodies which cause RANK L inhibition
BISPHOSPHONATES NON BISPHOSPHONATES
ZOLEDRONIC ACID Denosumab (rank l inhibitor)
(zometa)
IBANDRONATE (BONIVA)
tyrosine kinase inhibitor
monoclonal antibodies
Zometa molecule
RISEDRONATE targeting veg f
in blood stream + bone
, MRONJ: Pathophysiology
Mechanisms
1.Soft Tissue Toxicity 2. Impaired Bone Remodelling
3. Anti-Angiogenesis/
Microvascular injury
Salient information + drug info
MRONJ IS KNOWN AS MEDICATION RELATED OSTEONECROSIS OF THE JAW
MRONJ IS CAUSED BY BISPHOSPHONATES OR NON BISPHOSPHONATE MEDICATION
BISPHOSPHONATES ARE USED TO TREAT OSTEOPOROSIS, PAGET’S DISEASE AND SLOW CANCER SPREAD BY APOPTOSIS OF
OSTEOCLASTS (REDUCES RESORPTION OF BONE)
NON BISPHOSPHONATES ALSO TREAT THE SAME BONE CONDITions but have a different mechanism of action. They include
monoclonal antibodies which cause RANK L inhibition
BISPHOSPHONATES NON BISPHOSPHONATES
ZOLEDRONIC ACID Denosumab (rank l inhibitor)
(zometa)
IBANDRONATE (BONIVA)
tyrosine kinase inhibitor
monoclonal antibodies
Zometa molecule
RISEDRONATE targeting veg f
in blood stream + bone
, MRONJ: Pathophysiology
Mechanisms
1.Soft Tissue Toxicity 2. Impaired Bone Remodelling
3. Anti-Angiogenesis/
Microvascular injury
